Dr. Andrew Nash is the Chief Scientific Officer and Senior Vice President, Research at CSL Limited. After a PhD (1988) and academic career at The University of Melbourne, in 1996 he joined the ASX listed biotechnology company Zenyth Therapeutics as a senior scientist and subsequently held several positions including Director of Biologicals Research and Chief Scientific Officer. In July of 2005 he was appointed Chief Executive Officer of Zenyth, a position which he held up until the acquisition of Zenyth by CSL Limited in November 2006. Following the acquisition, he was appointed as CSL’s SVP, Research and is currently based at the Bio21 Institute where he leads a large global effort focused on the discovery and development of new protein, cell, and gene-based medicines. He was appointed as CSL’s Chief Scientific Officer in 2020.

A skilled, strategic leader, Brooke has more than two decades of experience driving strategic transformation through integrated change management, planning and performance monitoring across the higher education sector in Australia and the UK.

In her current position as inaugural Executive Director of the Randwick Health & Innovation Precinct (RHIP), Brooke leads a collaborative precinct partnership that brings together world-class education, research and healthcare organisations to address real-world problems in an integrated environment.

Prior to her role at the Precinct, Brooke held several senior positions at UNSW that saw her lead the emerging industry of Strategic Health, Education and Innovation Precincts, in addition to holding Faculty Executive Director positions in the Law and Business schools. Notably, Brooke also led the Operational Excellence Portfolio that implemented a new shared services model at the University.

Kim Sutherland is the Director of the Evidence team at Agency for Clinical Innovation (ACI), NSW Health. The team brings together expertise in synthesising research evidence from literature, data analytics and modelling, experiential evidence and evaluation. The Evidence team provides support to the Critical Intelligence Unit. Kim is a health services researcher with experience in performance measurement and reporting, evaluation and assessment of quality, and change management in healthcare organisations. Kim played a central role in the development of performance measurement frameworks in NSW and the UK and co-authored a series of reports on the English NHS quality agenda. Kim’s work has been published in 35 articles in the peer reviewed literature, with more than 3,500 citations. Kim holds a Master of Science from London Hospital Medical College, a Master of Business Administration from Imperial College London and a PhD from the University of Cambridge. In 2022, Kim received the Public Service Medal for outstanding public service to NSW Health.

Professor Robyn Ward (AM) is an academic leader, cancer researcher and clinician who has made significant contributions to health policy and practice in Australia, as well as to the higher education sector. Since 2018 she has served as Pro-Vice Chancellor Medicine and Health, and Executive Dean, Faculty of Medicine and Health, University of Sydney. Previous career roles included Deputy Vice Chancellor (Research) at the University of Queensland, as well as senior academic roles at UNSW Sydney.

Since 2009, Prof Ward has served as the inaugural Chair of the Commonwealth’s Medical Services Advisory Committee, advising the Commonwealth Health minister on the circumstances under which public funding should be provided for medical services, technologies and procedures. She is the longest-serving member of the Australian Commonwealth’s Pharmaceutical Benefits Advisory Committee (2000-2019), where her expertise in oncology and cancer biology helped evaluate the effectiveness and cost effectiveness of subsidising drugs, as well as developing policies regarding the best use of medicines in Australia. Over her research career, she has published over 270 original manuscripts that have been cited over 20,000 times by peers.

Among other roles, Prof Ward serves on the Council and Executive of the Australian Academy of Health and Medical Sciences, and on the board of Red Cross LifeBlood Australia and Telstra Health. She is the Australian Commonwealth representative for the Health Technology Assessment International (HTAi) group, and program director of eviQ for the NSW Cancer Institute. In 2013 Prof Ward was made a Member of the Order of Australia (AM) for significant service to medical research and patient care in the field of oncology.